Article info
PDFFrom the retired
Apolaustic apomorphine
- Correspondence to Dr Gerald Stern, Emeritus Consultant Neurologist, University College Hospitals, London WC1 3BG, UK; Geraldsterniii{at}gmail.com
Citation
Apolaustic apomorphine
Publication history
- Accepted January 11, 2013
- First published March 13, 2013.
Online issue publication
April 14, 2016
Article Versions
- Previous version (14 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
Other content recommended for you
- Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson’s disease
- Subcutaneous apomorphine in late stage Parkinson’s disease: a long term follow up
- Parkinson’s disease: etiopathogenesis and treatment
- Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies
- What to do when people with Parkinson's disease cannot take their usual oral medications
- Response of parkinsonian swallowing dysfunction to dopaminergic stimulation
- When the going gets tough: how to select patients with Parkinson's disease for advanced therapies
- Drugs for Parkinson’s disease
- Deep brain stimulation of the subthalamic nucleus: effectiveness in advanced Parkinson’s disease patients previously reliant on apomorphine
- Developments in the treatment of Parkinson's disease